Trials / Completed
CompletedNCT00891137
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Cellerant Therapeutics · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic cancer. In this study, the safety and tolerability of CLT-008 administered 24 hours after an umbilical cord blood transplant will be determined by monitoring for adverse reactions, neutrophil and platelet recovery, hematopoietic chimerism, graft-versus-host disease (GVHD), and infections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | human myeloid progenitor cells | Single intravenous injection/infusion |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2009-05-01
- Last updated
- 2014-10-27
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00891137. Inclusion in this directory is not an endorsement.